Juan Ignacio Marín-Zuluaga

Juan Ignacio Marín-Zuluaga

Auto-generated profile, based on publicly available information

Juan Ignacio Marín-Zuluaga

Hospital Pablo Tobón Uribe

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 July 2013 in Journal of Medical Case Reports
Verified
Journal Article
Open access
PDF file
JZJuan Ignacio Marin Zuluaga
Juan Ignacio Marin Zuluaga
ACAndres Eduardo Marin Castro
Andres Eduardo Marin Castro
JCJuan Camilo Perez Cadavid
Juan Camilo Perez Cadavid
JGJuan Carlos Restrepo Gutierrez
Juan Carlos Restrepo Gutierrez
Drug-related hepatotoxicity is a common medical problem with implications for health systems. It constitutes a cause of acute liver failure and, in many cases, is responsible for the rejection of new pharmacological agents during efficacy and safety studies. Risk factors, as well as pathogenesis of drug-induced liver injury, are poorly understood. The diagnosis of drug-induced liver injury is challenging; it is difficult to define the cause of drug hepatotoxicity due to the heterogeneity of the clinical presentation and the absence of established criteria for accurate and reproducible identification of drug-associated liver toxicity.

24 May 2018 in JGH Open
Verified
Journal Article
Open access
PDF file
OMOmar Yesid Martínez‐Casas
Omar Yesid Martínez‐Casas
GDGabriel Sebastián Díaz‐Ramírez
Gabriel Sebastián Díaz‐Ramírez
JMJuan Ignacio Marín‐Zuluaga
Juan Ignacio Marín‐Zuluaga
OMOctavio Muñoz‐Maya
Octavio Muñoz‐Maya
OSOscar Santos
Oscar Santos
JRJuan Carlos Restrepo‐Gutiérrez
Juan Carlos Restrepo‐Gutiérrez
Background and Aim: Drug‐induced autoimmune hepatitis (DIAIH) is an adverse effect associated with several drugs that usually occurs acutely, with variable latency, and it may potentially be mortal. There are a few reports and studies about DIAIH.Methods: This was an analytical study of a retrospective cohort of patients, discriminated according to idiopathic or drug‐induced etiology, followed up for a 7‐year period until 31 December 2016.Results: A total of 190 patients were selected for the analysis, 12 (6.3%) with DIAIH. The two main drugs related to DIAIH were nitrofurantoin, n = 8 (67%), and NSAID, n = 2 (17%), constituting 84% of the cases. There were no significant differences in seropositivity between AIH with DIAIH in antinuclear antibodies (ANA) and anti‐smooth muscle antibodies (ASMA) antibodies, with 82.6% versus 82.6% and 34% versus 16%, respectively. The fibrosis stages were similar, except for the F4 stage, in a greater proportion in AIH. None of the patients with DIAIH had cirrhosis or developed it during follow‐up, but it was present in 42.1% of the AIH cases at diagnosis (P = 0.003). Biochemical remission with management was higher in DIAIH but not significant (91.7% vs 80.9%, P = 0.35). The definitive interruption of immunosuppression was successfully performed in 25% of those with DIAIH without relapses but was only possible in 2.8% in AIH (P < 0.001) with 32 cases of relapses.Conclusion: DIAIH constitutes a minor proportion of AIH. The clinical and histological characteristics may be similar; DIAIH patients have a greater chance of having treatment suspended with a low risk of relapse, progression to cirrhosis, or need for liver transplant.

18 September 2008 in Respiration
Verified
Journal Article
Closed access
PDF file
LPLuis Fernando Pinto
Luis Fernando Pinto
LCLiliana Candia
Liliana Candia
PGPatricia Garcia
Patricia Garcia
JMJuan Ignacio Marín
Juan Ignacio Marín
IPInes Pachón
Ines Pachón
JMJavier Marquez
Javier Marquez
We report a 19-year-old female with systemic lupus erythematosus and lupus nephritis who developed pulmonary hemorrhage (PH) refractory to conventional immunosuppressive treatment. She was initially treated with intravenous methylprednisolone and cyclophosphamide pulses. She required mechanical ventilation due to a lack of responsiveness and her disease was considered refractory to conventional treatment. Rituximab was administered and this was followed by clinical improvement in both PH and nephritis. Rituximab may be a useful therapeutic option for the treatment of refractory PH.

14 March 2020 in Liver International
Verified
Journal Article
Closed access
PDF file
ÁDÁlvaro Díaz-González
Álvaro Díaz-González
MZMarco Sanduzzi Zamparelli
Marco Sanduzzi Zamparelli
LFLeonardo Da Fonseca
Leonardo Da Fonseca
GCGiovan Giuseppe Di Costanzo
Giovan Giuseppe Di Costanzo
RARogerio Alves
Rogerio Alves
MRMaria Reig
Maria Reig

1 February 2018 in Gastroenterología y Hepatología
Verified
Journal Article
Closed access
GDGabriel Sebastián Díaz-Ramírez
Gabriel Sebastián Díaz-Ramírez
JMJuan Ignacio Marín-Zuluaga
Juan Ignacio Marín-Zuluaga
JDJorge Hernando Donado-Gómez
Jorge Hernando Donado-Gómez
OMOctavio Muñoz-Maya
Octavio Muñoz-Maya
ÓSÓscar Santos-Sánchez
Óscar Santos-Sánchez
JRJuan Carlos Restrepo-Gutiérrez
Juan Carlos Restrepo-Gutiérrez

1 November 2018 in Gastroenterología y Hepatología
Verified
Journal Article
Closed access
OCOmar Yesid Martínez Casas
Omar Yesid Martínez Casas
GRGabriel Sebastián Díaz Ramírez
Gabriel Sebastián Díaz Ramírez
JZJuan Ignacio Marín Zuluaga
Juan Ignacio Marín Zuluaga
ÓSÓscar Santos
Óscar Santos
OMOctavio Muñoz Maya
Octavio Muñoz Maya
JGJuan Carlos Restrepo Gutiérrez
Juan Carlos Restrepo Gutiérrez